Posted on December 7, 2011
This entry was posted in Positioning- Lower Limmb.
Wow, great article post.Thanks Again. Great.
electricien 78 yvelines
I really like and appreciate your article post.Thanks Again. Awesome.
serrurier 95 val-d’oise
Great, thanks for sharing this article.Much thanks again. Great.
Im obliged for the blog post. Will read on…
best tablets on the market
Wow, great blog article.Thanks Again. Will read on…
Ice Cream Delivery
I really like and appreciate your post.Much thanks again. Will read on…
Great, thanks for sharing this blog post.Really looking forward to read more. Will read on…
serrurier 92 hauts-de-seine
I loved your blog article. Want more.
arapahoe county bail bonds
Wow, great blog post.Really looking forward to read more. Great.
electricians in columbia sc
Thanks for sharing, this is a fantastic blog article.Really looking forward to read more. Awesome.
catering services in columbia sc
Thanks-a-mundo for the blog article.Really looking forward to read more.
Appreciate you sharing, great blog post. Much obliged.
Thanks for the blog article.Really looking forward to read more. Will read on…
Im obliged for the blog.Much thanks again. Want more.
sales tools for home care agencies
Major thankies for the blog post.Really thank you! Much obliged.
Immobilienkauf in Alanya
Very good blog article. Cool.
Say, you got a nice article post.Really looking forward to read more. Cool.
Entretien mГ©nager Г montrГ©al
Enjoyed every bit of your post. Awesome.
indianapolis search engine optimization
Thanks again for the blog article.Really looking forward to read more. Fantastic.
I value the blog post.Really looking forward to read more. Will read on…
ant trap hummingbird
wow, awesome blog.Thanks Again. Cool.
car body repairs in leeds
Thanks for sharing, this is a fantastic post.Really looking forward to read more. Will read on…
wall stencils uk
Oncology clinicians may soon have hundreds of biomarker tests available to them to assist in developing personalized cancer treatments, but some healthcare professionals believe that novel funding approaches for biomarker tests’ studies—a systematic process to move biomarker tests through regulatory agencies and a body of evidence supporting biomarker tests’ benefits—will all be necessary before healthcare system stakeholders accept their use.
In the December issue of Health Affairs, Scott D. Ramsey, MD, PhD, of the Seattle-based Fred Hutchinson Cancer Research Center and his colleagues proposed a framework for the integrated approach to designing and implementing comparative clinical trials of personalized medicine technologies, including the use of biomarker tests.
Biomarker tests, also known as genomic tests, are used to measure the unique variables of individuals’ genetic material, proteins and other biological molecules. Those measurements can be used to develop individual assessments of the risk of future disease, the aggressiveness of a disease and possible outcomes of different treatments.
Ramsey and his colleagues believe that biomarker tests, which are often introduced into clinical practice without sufficient evidence of their benefits, have “tremendous potential for improved outcomes and lower treatment costs,” but propose comparative effectiveness research to “strengthen what is now a haphazard process for developing and marketing cancer biomarker tests.”
The researchers wrote, “Comparative effectiveness research will be more important at the intersection of personalized medicine and cancer than anywhere else because of the high risks and costs of poor-quality test information about this group of diseases.”
Ramsey and his colleagues suggested that future clinical trials of biomarker tests:
•Identify personalized medicine technologies that multiple stakeholder groups, specifically consumers and clinicians, consider high-priority;
•Be designed to meet the needs of multiple stakeholders;
•Use clinical trial groups with standing infrastructures in order to conduct studies on a large scale; and
•Employ funding mechanisms that distribute costs among private and public insurers.
“For such an approach to be viable,” Ramsey and colleagues wrote, “clinical trials groups, insurers and other interested stakeholders will need to develop standardized methods for assessing clinical validity and clinical utility, particularly in the context of rapidly evolving technology; establish a network of clinical organizations capable of rapidly enrolling patients in these studies; and develop collaborative mechanisms so that payers, clinicians, patients and researchers can work together to design, fund and implement studies.”
Fill in your details below or click an icon to log in:
You are commenting using your WordPress.com account.
( Log Out /
You are commenting using your Google+ account.
( Log Out /
You are commenting using your Twitter account.
( Log Out /
You are commenting using your Facebook account.
( Log Out /
Connecting to %s
Notify me of new comments via email.
Notify me of new posts via email.